5 January 2021
Erythromycin in babies and infants has been associated with an increased risk of infantile hypertrophic pyloric stenosis.
14 December 2020
This guidance, updated in December 2020 and endorsed by RCPCH, has been produced to inform all healthcare professionals of best practice around the use and prescribing of valproate. It supports them to navigate situations that could arise as a result of prescribing valproate to women during childbea...
14 December 2020
Experts from 13 national bodies, including seven Royal Colleges, have joined forces to launch new practical guidance to support doctors and other health professionals around valproate use in women and girls in their reproductive years.
9 September 2020
Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the World Health Organization (WHO) has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease.
26 June 2020
Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019, because of fears that they may contain low levels of an impurity called NMDA.
This new microsite is your essential resource on child protection and safeguarding - whether you are involved with child protection as a child health professional, allied health professional, social worker, solicitor or barrister.
17 March 2020
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
2 March 2020
The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.
5 February 2020
Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.
The Medicines and Healthcare products Regulatory Agency (MHRA) “Yellow Card Scheme” is the UK system for collecting and monitoring information on suspected safety concerns or incidents involving side effects to medicines (also known as adverse drug reactions or ADRs) and medical devices.